Compositions and methods for treating antibiotic resistance
AssigneeSeres Therapeutics, Inc.
InventorsChristopher Burton Ford, Jessica Bryant, Edward J. O'Brien
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for reducing the carriage of antibiotic resistance genes.
Claims20
A method of reducing an abundance of at least one antibiotic-resistance gene in the microbiome of a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a combination of bacteria, the combination comprising Blautia wexlerae and Anaerotruncus colihominis, wherein after the administration of the composition, the abundance of the at least one antibiotic-resistance gene in the microbiome of the subject is reduced as compared to a corresponding subject who did not receive the administration of the composition, wherein the at least one antibiotic-resistance gene is capable of conferring resistance to beta-lactam antibiotics and at least one additional antibiotic drug class, and wherein:
- (a) the Blautia wexlerae comprises a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequence set forth in any one of SEQ ID NOs:
- 104-110 and 255;
- and
- (b) the Anaerotruncus colihominis comprises a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequence set forth in any one of SEQ ID NOs:
- 89-92.
A method of treating a mammalian subject at risk for or diagnosed with an undesirable level of bacteria that are resistant to multiple antibiotic drug classes, comprising administering to the subject a therapeutically effective amount of a composition comprising a combination of bacteria, wherein the combination comprises Blautia wexlerae and Anaerotruncus colihominis, wherein the undesirable level is a level significantly greater than that in a healthy subject population and the multiple antibiotic drug classes comprise beta-lactam antibiotics and at least one additional antibiotic drug class, and wherein:
- (a) the Blautia wexlerae comprises a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequence set forth in any one of SEQ ID NOs:
- 104-110 and 255;
- and
- (b) the Anaerotruncus colihominis comprises a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequence set forth in any one of SEQ ID NOs:
- 89-92.
Dependencies are inferred from the claim text.